Results 1 to 10 of about 30,054 (166)

JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison [PDF]

Cancer Medicine
Background Giant cell tumors of bone (GCTB) are RANK/RANK‐ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients.
Hairong Xu, Yong Zhou, Feng Wei, Yi Ding, Huachao Shan, Yongkun Yang, Weifeng Liu, Tao Jin, Yi Luo, Fan Tang, Minxun Lu, Xin He, Wenli Zhang, Shaomin Yang, Lihua Zhang, Juan Wang, Hong Li, Chongqi Tu, Xiaohui Niu   +18 more
doaj   +2 more sources

Oral management of patients treated with denosumab for giant cell tumor of bone: A retrospective study at the University Hospitals of Strasbourg

Oral Oncology Reports, 2023
Objectives: Giant cell tumor of bone (GCTB) is defined as a rare intermediate-grade mesenchymal tumor. The first-line treatment was surgery but since the 2010s, denosumab is a medical therapeutic option that can stop progression of GCTBs with a high ...
P. Klienkoff, N. Weingertner, J.-E. Kurtz, F. Bornert   +3 more
doaj   +1 more source

The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases

Pathology and Oncology Research, 2022
Due to the relatively high recurrence rate and the destructive nature of the tumor, the treatment of giant cell tumor is still a challenge. Denosumab appeared to be a promising candidate as a therapeutic drug.
Imre Antal, Zsuzsanna Pápai, Miklós Szendrői, Tamás Perlaky, Katalin Dezső, Zoltán Lippai, Zoltán Sápi   +6 more
doaj   +1 more source

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach

Journal of Bone Oncology, 2022
Background: Clinical practice guidelines recommend the use of bone-targeting agents for preventing skeletal-related events (SREs) among patients with bone metastases from solid tumors.
Dionna Jacobson, Benoit Cadieux, Celestia S. Higano, David H. Henry, Basia A. Bachmann, Marko Rehn, Alison T. Stopeck, Hossam Saad   +7 more
doaj   +1 more source

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Scientific Reports, 2022
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this
Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Ki-Yeol Kim, Hyung Jun Kim, Wonse Park   +5 more
doaj   +1 more source

Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching

Cancer Medicine, 2023
Background and Objectives Denosumab is recommended for advanced giant cell tumor of bone (GCTB) that is unresectable or resectable with unacceptable morbidity.
Yongfu Huang, Mingxian Xu, Bo Wang, Zhiqiang Zhao, Tiao Lin, Gang Huang, Junqiang Yin, Xianbiao Xie, Jingnan Shen, Changye Zou   +9 more
doaj   +1 more source

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

Frontiers in Oncology, 2023
Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption.
Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, Bo Shuai   +5 more
doaj   +1 more source

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases [PDF]

, 2015
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC).
A Hussain, A Lipton, A Lipton, Ada Braun, Alison Stopeck, AM Abdulhalim, Arun Balakumaran, AT Stopeck, Blair Egerdie, C Nieder, Charles Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, D Henry, Danail Damyanov, DF Cella, DH Henry, Donald L. Patrick, E Chow, F Saad, Felipe Salvador Palazzo, G Oster, Gavin Marx, GD Roodman, GR Mundy, GV Scagliotti, JA Ford, Janet Brown, Jean-Jacques Body, K Cetin, K Fizazi, K Fizazi, K Lemay, K Webster, KC Chung, L Costa, L Costa, L Costa, Lesley Fallowfield, LS Rosen, M Maltoni, M Norgaard, M Yong, MR Smith, N Sathiakumar, N Sathiakumar, R Moos von, R Moos von, RE Coleman, RE Coleman, Roger von Moos, S Vadhan-Raj, Yi Qian, Ying Zhou   +55 more
core   +5 more sources

Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

BMC Musculoskeletal Disorders, 2020
Background In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity.
Xi Chen, Hairui Li, Shibai Zhu, Yiou Wang, Wenwei Qian   +4 more
doaj   +1 more source

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Frontiers in Endocrinology, 2021
ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment.
Yasuaki Hirooka, Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +7 more
doaj   +1 more source